Pasithea raises ~$60M in public offering of common stock and pre-funded warrants

Pasithea Therapeutics Corp.

Gross proceeds of $60.0M; net proceeds of ~$54.9M after fees and expenses.
Offering priced at $0.75 per share/warrant; 80M shares (or pre-funded warrants) sold.
Led by healthcare investors including Vivo Capital, Janus Henderson, Coastlands Capital.
Insiders (CEO, CFO, board members) bought 400k shares at same price.
Cash runway extended through at least first half 2028.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Pasithea Therapeutics Corp. issued 4,000,000 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC or its designees.

Security: warrant
Shares: 4,000,000 shares of Common Stock
Purchaser: H.C. Wainwright & Co., LLC or its designees

Exact text from the filing

the Company issued to Wainwright or its designees, warrants (the “ Placement Agent Warrants ”) to purchase up to an aggregate of 4,000,000 shares of Common Stock (the “ Placement Agent Warrant Shares ”) at an exercise price equal to $0.9375 per share

View on SEC.gov

11 equity issuances filed in the last 30 days. Browse all equity issuances →

Pasithea Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001213900-25-116985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.